Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Emmy Boerrigter, Levi N. Groen, Nielka P. Van Erp, Gerald W. Verhaegh & Jack A. Schalken. (2020) Clinical utility of emerging biomarkers in prostate cancer liquid biopsies. Expert Review of Molecular Diagnostics 20:2, pages 219-230.
Read now
Read now
Guo-qiang Qin, Hui-chan He, Zhao-dong Han, Yu-xiang Liang, Sheng-bang Yang, Ya-qiang Huang, Liang Zhou, Hao Fu, Jie-xian Li, Fu-neng Jiang & Wei-de Zhong. (2014) Combined overexpression of HIVEP3 and SOX9 predicts unfavorable biochemical recurrence-free survival in patients with prostate cancer. OncoTargets and Therapy 7, pages 137-146.
Read now
Read now
Articles from other publishers (32)
Mohamed Youssef, Nermine Moussa, Maged W. Helmy & Medhat Haroun. (2022) Unraveling the therapeutic potential of GANT61/Dactolisib combination as a novel prostate cancer modality. Medical Oncology 39:10.
Crossref
Crossref
Hao-Wen Chuang, Jian-Hua Pan, Yi-Xuan Cai, Darius Rupa, Ting-Syuan Huang, Tzu-Chien Kuo, Chiao-Wen Lin, Chi-Wei Chen, Chia-Chin Lin, Herng-Sheng Lee & Ta-Chun Yuan. (2022) Reciprocal regulation of CIP2A and AR expression in prostate cancer cells. Discover Oncology 13:1.
Crossref
Crossref
Yashika Jawa, Sangeeta Kumari, Gargi Bagchi & Rakesh K. Tyagi. 2022. Post-Transcriptional Gene Regulation in Human Disease. Post-Transcriptional Gene Regulation in Human Disease
149
165
.
Niklas Klümper, Marthe von Danwitz, Johannes Stein, Doris Schmidt, Anja Schmidt, Glen Kristiansen, Michael Muders, Michael Hölzel, Manuel Ritter, Abdullah Alajati & Jörg Ellinger. (2020) Downstream Neighbor of SON (DONSON) Expression Is Enhanced in Phenotypically Aggressive Prostate Cancers. Cancers 12:11, pages 3439.
Crossref
Crossref
Mary-Ellen Taplin, Emmanuel S. Antonarakis, Karen J. Ferrante, Kerry Horgan, Brent Blumenstein, Fred Saad, Jun Luo & Johann S. de Bono. (2019) Androgen Receptor Modulation Optimized for Response—Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7–expressing Metastatic Castration-resistant Prostate Cancer. European Urology 76:6, pages 843-851.
Crossref
Crossref
Xiaodong Chen, Feng Chen, Yu Ren, Guobin Weng, Peter C. Keng, Yuhchyau Chen & Soo Ok Lee. (2019) Glucocorticoid receptor upregulation increases radioresistance and triggers androgen independence of prostate cancer. The Prostate 79:12, pages 1414-1426.
Crossref
Crossref
Ezgi Avsar Abdik, Ferda Kaleagasioglu, Hüseyin Abdik, Fikrettin Sahin & Martin R. Berger. (2019) ABT-737 and erufosine combination against castration-resistant prostate cancer. Anti-Cancer Drugs 30:4, pages 383-393.
Crossref
Crossref
Michael Mark, Dirk Klingbiel, Ulrich Mey, Ralph Winterhalder, Christian Rothermundt, Silke Gillessen, Roger von Moos, Michael Pollak, Gabriela Manetsch, Räto Strebel & Richard Cathomas. (2019) Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study. Clinical Genitourinary Cancer 17:2, pages e323-e328.
Crossref
Crossref
Michael T. Schweizer, Kathleen Haugk, Jožefa S. McKiernan, Roman Gulati, Heather H. Cheng, Jessica L. Maes, Ruth F. Dumpit, Peter S. Nelson, Bruce Montgomery, Jeannine S. McCune, Stephen R. Plymate & Evan Y. Yu. (2018) A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. PLOS ONE 13:6, pages e0198389.
Crossref
Crossref
S. Prekovic, T. Van den Broeck, L. Moris, E. Smeets, F. Claessens, S. Joniau, C. Helsen & G. Attard. (2018) Treatment-induced changes in the androgen receptor axis: Liquid biopsies as diagnostic/prognostic tools for prostate cancer. Molecular and Cellular Endocrinology 462, pages 56-63.
Crossref
Crossref
Gianmarco Leone, Marcello Tucci, Consuelo Buttigliero, Clizia Zichi, Daniele Pignataro, Paolo Bironzo, Francesca Vignani, Giorgio V Scagliotti & Massimo Di Maio. (2018) Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer. Endocrine-Related Cancer 25:1, pages R1-R9.
Crossref
Crossref
Nancy Devlin, Michael Herdman, Marco Pavesi, De Phung, Shevani Naidoo, Tomasz M. Beer, Bertrand Tombal, Yohann Loriot, Cristina Ivanescu, Teresa Parli, Mark Balk & Stefan Holmstrom. (2017) Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial. Health and Quality of Life Outcomes 15:1.
Crossref
Crossref
Daniele Marcoccia, Marco Pellegrini, Marco Fiocchetti, Stefano Lorenzetti & Maria Marino. (2017) Food components and contaminants as (anti)androgenic molecules. Genes & Nutrition 12:1.
Crossref
Crossref
Vincent Liu, Wing Yau, Chun Tam, Kwok-Ming Yao & Stephen Shiu. (2017) Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy. International Journal of Molecular Sciences 18:6, pages 1130.
Crossref
Crossref
J. Morote, L. Regis, A. Celma & J. Planas. (2016) Measurement of serum testosterone during androgenic suppression in patients with prostate cancer: A systematic review. Actas Urológicas Españolas (English Edition) 40:8, pages 477-484.
Crossref
Crossref
J. Morote, L. Regis, A. Celma & J. Planas. (2016) Determinación de la testosterona sérica durante la supresión androgénica en pacientes con cáncer de próstata: una revisión sistemática. Actas Urológicas Españolas 40:8, pages 477-484.
Crossref
Crossref
Jack Schalken & John M. Fitzpatrick. (2016) Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. BJU International 117:2, pages 215-225.
Crossref
Crossref
Michael T. Schweizer & Evan Y. Yu. (2015) Persistent androgen receptor addiction in castration-resistant prostate cancer. Journal of Hematology & Oncology 8:1.
Crossref
Crossref
Yuanyuan Qu, Bo Dai, Dingwei Ye, Yunyi Kong, Kun Chang, Zhongwei Jia, Xiaoqun Yang, Hailiang Zhang, Yao Zhu & Guohai Shi. (2015) Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer. Scientific Reports 5:1.
Crossref
Crossref
Sarah K. Martin & Natasha Kyprianou. 2015.
123
158
.
Styliani Karanika, Theodoros Karantanos, Jianhua Yin, Likun Li & Timothy C. Thompson. (2014) WITHDRAWN: Novel anti-androgen receptor signaling agents: Understanding the mechanisms of resistance. Asian Journal of Urology.
Crossref
Crossref
H. Pu, C. Horbinski, P. J. Hensley, E. A. Matuszak, T. Atkinson & N. Kyprianou. (2014) PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis. Carcinogenesis 35:11, pages 2592-2601.
Crossref
Crossref
Styliani Karanika, Theodoros Karantanos, Jianhua Yin, Likun Li & Timothy C. Thompson. (2014) Novel anti-androgen receptor signaling agents: Understanding the mechanisms of resistance. Asian Journal of Urology 1:1, pages 30-39.
Crossref
Crossref
Mary Nakazawa, Emmanuel S. Antonarakis & Jun Luo. (2014) Androgen Receptor Splice Variants in the Era of Enzalutamide and Abiraterone. Hormones and Cancer 5:5, pages 265-273.
Crossref
Crossref
Cynthia C. T. Sprenger & Stephen R. Plymate. (2014) The Link Between Androgen Receptor Splice Variants and Castration-Resistant Prostate Cancer. Hormones and Cancer 5:4, pages 207-217.
Crossref
Crossref
Cora N. SternbergDaniel P. PetrylakRavi A. MadanChris Parker. (2014) Progress in the Treatment of Advanced Prostate Cancer. American Society of Clinical Oncology Educational Book:34, pages 117-131.
Crossref
Crossref
Sarah K. Martin, Michael V. Fiandalo & Natasha Kyprianou. 2013. Androgen-Responsive Genes in Prostate Cancer. Androgen-Responsive Genes in Prostate Cancer
227
255
.
Stephen R. Plymate & Jun Luo. 2013. Androgen-Responsive Genes in Prostate Cancer. Androgen-Responsive Genes in Prostate Cancer
201
213
.
Wei-de Zhong, Guo-qiang Qin, Qi-shan Dai, Zhao-dong Han, Shan-ming Chen, Xiao-hui Ling, Xin Fu, Chao Cai, Jia-hong Chen, Xi-bin Chen, Zhuo-yuan Lin, Ye-han Deng, Shu-lin Wu, Hui-chan He & Chin-lee Wu. (2012) SOXs in human prostate cancer: implication as progression and prognosis factors. BMC Cancer 12:1.
Crossref
Crossref
Faris Azzouni & James Mohler. (2012) Biology of Castration-Recurrent Prostate Cancer. Urologic Clinics of North America 39:4, pages 435-452.
Crossref
Crossref
Saroj Niraula, Kim Chi & Anthony Michael Joshua. (2011) Beyond Castration—Defining Future Directions in the Hormonal Treatment of Prostate Cancer. Hormones and Cancer 3:1-2, pages 3-13.
Crossref
Crossref
Rong Hu, William B. Isaacs & Jun Luo. (2011) A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. The Prostate 71:15, pages 1656-1667.
Crossref
Crossref